This article is from the source 'bbc' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at http://www.bbc.co.uk/news/health-25207033
The article has changed 2 times. There is an RSS feed of changes available.
Previous version
1
Next version
Version 0 | Version 1 |
---|---|
TB vaccine 'could help prevent MS' | TB vaccine 'could help prevent MS' |
(about 1 hour later) | |
An anti-tuberculosis vaccine could prevent multiple sclerosis, early research suggests. | An anti-tuberculosis vaccine could prevent multiple sclerosis, early research suggests. |
A small-scale study by researchers at the Sapienza University of Rome has raised hopes that the disease can be warded off when early symptoms appear. | A small-scale study by researchers at the Sapienza University of Rome has raised hopes that the disease can be warded off when early symptoms appear. |
More research is needed before the BCG vaccine can be trialled on MS patients. | More research is needed before the BCG vaccine can be trialled on MS patients. |
The MS Society said the chance to take a safe and effective preventative treatment after a first MS-like attack would be a huge step forward. | The MS Society said the chance to take a safe and effective preventative treatment after a first MS-like attack would be a huge step forward. |
MS is a disease affecting nerves in the brain and spinal cord, causing problems with muscle movement, balance and vision. | MS is a disease affecting nerves in the brain and spinal cord, causing problems with muscle movement, balance and vision. |
Early signs include numbness, vision difficulties or problems with balance. | Early signs include numbness, vision difficulties or problems with balance. |
About half of people with a first episode of symptoms go on to develop MS within two years, while 10% have no more problems. | About half of people with a first episode of symptoms go on to develop MS within two years, while 10% have no more problems. |
In the study, published in the journal Neurology, Italian researchers gave 33 people who had early signs of MS an injection of BCG vaccine. | In the study, published in the journal Neurology, Italian researchers gave 33 people who had early signs of MS an injection of BCG vaccine. |
The other 40 individuals in the study were given a placebo. | The other 40 individuals in the study were given a placebo. |
After five years, 30% of those who received the placebo had not developed MS, compared with 58% of those vaccinated. | |
"These results are promising, but much more research needs to be done to learn more about the safety and long-term effects of this live vaccine," said study leader Dr Giovanni Ristori. | "These results are promising, but much more research needs to be done to learn more about the safety and long-term effects of this live vaccine," said study leader Dr Giovanni Ristori. |
"Doctors should not start using this vaccine to treat MS or clinically isolated syndrome." | "Doctors should not start using this vaccine to treat MS or clinically isolated syndrome." |
Dr Susan Kohlhaas, head of biomedical research at the MS Society, said it was a small but interesting study. | Dr Susan Kohlhaas, head of biomedical research at the MS Society, said it was a small but interesting study. |
"It's really encouraging to see positive results from this small trial, but they'll need validating in larger and longer-term studies before we know if the BCG vaccination can reduce the risk of someone developing MS. | "It's really encouraging to see positive results from this small trial, but they'll need validating in larger and longer-term studies before we know if the BCG vaccination can reduce the risk of someone developing MS. |
"Ultimately, the chance to take a safe and effective preventative treatment after a first MS-like attack would be a huge step forward." | "Ultimately, the chance to take a safe and effective preventative treatment after a first MS-like attack would be a huge step forward." |
The findings add weight to a theory that exposure to infections early in life might reduce the risk of diseases such as MS by stimulating the body's immune system. | The findings add weight to a theory that exposure to infections early in life might reduce the risk of diseases such as MS by stimulating the body's immune system. |
Dr Dennis Bourdette, of Oregon Health and Science University in Portland, US, said the research suggested "BCG could prove to be a 'safe, inexpensive, and handy' treatment for MS". | Dr Dennis Bourdette, of Oregon Health and Science University in Portland, US, said the research suggested "BCG could prove to be a 'safe, inexpensive, and handy' treatment for MS". |
He wrote in an accompanying editorial in Neurology: "The theory is that exposure to certain infections early in life might reduce the risk of these diseases by inducing the body to develop a protective immunity." | He wrote in an accompanying editorial in Neurology: "The theory is that exposure to certain infections early in life might reduce the risk of these diseases by inducing the body to develop a protective immunity." |
Previous version
1
Next version